Tart cherry for mild to moderate Crohn's disease
Part of Digestive system clinical trials.
This study tests whether drinking tart cherry juice can help reduce symptoms of Crohn's disease. It may offer a natural way to support your current treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a Crohn's disease diagnosis for at least 6 months.
- Your Crohn's disease is currently mild to moderate.
- You are between 18 and 65 years old.
- You have been on a stable medication plan for at least 3 months.
- You do not have diabetes, HIV, hepatitis B or C, or any abscesses.
- You are not allergic to cherries.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This study tests whether a specially designed anti-inflammatory American diet can help control mild to moderate Crohn's Disease symptoms. Participants will follow a diet plan, with guidance from the research team, to see if it reduces inflammation and improves quality of life.
This study looks at how changing your diet might help people with Crohn's disease feel better. It is for adults with mild to moderate Crohn's who are not using a liquid-only diet and have not had recent surgery.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.